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Glioblastoma multiforme is the most aggressive astrocytoma characterized by the development of
resistant cells to various cytotoxic stimuli. Nitric oxide (NO) is able to overcome tumor resistance in PTEN
mutated rat C6 glioma cells due to its ability to inhibit cell growth by influencing the intracellular
distribution of ceramide. The aim of this study is to monitor the eﬀects of NO donor PAPANONOate on
ceramide traﬃcking in human glioma cell lines, CCF-STTG1 (PTEN-mutated, p53-wt) and T98G (PTEN-
harboring, p53-mutated), together with the assessment of their diﬀerential molecular signature by
2D-DIGE and MALDI mass spectrometry. In the CCF-STTG1 cell line, the results indicate that treatment
with PAPANONOate decreased cell proliferation (o50%) and intracellular traﬃcking of ceramide, assessed
by BODIPY-C5Cer, while these events were not observed in the T98G cell line. Proteomic results suggest
that CCF-STTG1 cells are characterized by an increased expression of proteins involved in NO-associated
ER stress (i.e. protein disulfide-isomerase A3, calreticulin, 78 kDa glucose-regulated protein), which could
compromise ceramide delivery from ER to Golgi, leading to ceramide accumulation in ER and partial
growth arrest. Conversely, T98G cell lines, resistant to NO exposure, are characterized by increased levels
of cytosolic antioxidant proteins (i.e. glutathione-S-transferase P, peroxiredoxin 1), which might buﬀer
intracellular NO. By providing diﬀerential ceramide distribution after NO exposure and diﬀerential protein
expression of two high grade glioma cell lines, this study highlights specific proteins as possible markers
for tumor aggressiveness. This study demonstrates that, in two diﬀerent high grade glioma cell lines, NO
exposure results in a diﬀerent ceramide distribution and protein expression. Furthermore, this study
highlights specific proteins as possible markers for tumor aggressiveness.
1. Introduction
Anaplastic astrocytomas and glioblastoma multiforme (GBM)
are high grade brain tumors originating from astrocytes;1 the
latter (WHO grade IV) is the most aggressive, being highly
invasive and vascularized, with a median survival lower than
one year in the 95% of cases.2 Due to its aggressiveness,
chemoresistance and adverse prognosis, the discovery of new
therapeutic agents remains a crucial point. Several eﬀorts have
been made to elucidate the GBM molecular gene signatures;3
the results demonstrate that frequent gene mutations, located
in many genes, including p53, isocitrate dehydrogenase (IDH),
phosphatidylinositol 3-kinase (PI3K) phosphatase and tensin
homologue (PTEN), as well as an unmethylated O6-methylguanine
methyltransferase (MGMT) promoter, contribute to radio- and
chemo-resistance and correlate with poor survival. Furthermore,
the infiltrative growth of GBM causes tumor recurrence at the
margin of the surgical resection area.3
Currently, GBM therapy involves the administration of the
alkylating agent temozolomide (TMZ) in conjugation with radio-
therapy4 or treatment with Carmustine, 1,3-bis(2-chloroethyl)-1-
nitrosourea (BCNU) in situ, after resection.5 Evidence indicates that
in gliomas, as in extraglial tumors, the sphingolipid metabolite
ceramide (Cer) plays an important role as a tumor suppressor being
involved in the action of diﬀerent chemotherapeutic drugs,6,7
nevertheless the ceramide-mediated cell death escape7,8 remains
a critical point.
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To overcome chemoresistance, new agents in combination
with chemotherapy have been considered, among these, nitric
oxide (NO) has emerged as a potent chemosensitizer for glioma
treatments.9–11 NO is a water-soluble highly reactive free radical,
with a major role as a vascular relaxing agent, an inhibitor of
platelet aggregation and a neurotransmitter. It can act as an anti-
inflammatory, a pro-inflammatory or a cytotoxic agent, inducing
cell death through apoptosis or necrosis. NO concentration plays
a fundamental role in its activity, by a cGMP dependent (at low
concentration, i.e. nM) or independent (at high concentration,
i.e. 1 mM) mechanism. A previous study demonstrated that
treatments with rapid NO releasing donors PAPANONOate ((Z)-
[N-(3-ammoniopropyl)-N-(npropyl) amino]diazen-1-ium-1,2-diolate)
inhibited rat C6 glioma cell line growth in a dose dependent-
manner (via a cGMP-independent mechanism). This inhibition is
accompanied by a rapid and significant increase of ceramide in
endoplasmic reticulum (ER), presumably, caused by a reduction of
ceramide trafficking from ER to Golgi, blunting its conversion into
complex sphingolipids.12,13 It is also known that the PI3K/Akt
(phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B)
pathway regulates ceramide metabolism through a positive control
of the vesicular ER to Golgi transport.14 Other studies, in ovarian
cancer cell, demonstrated that NO donors induced a decrement of
Akt phosphorylation causing cell death, suggesting that NO donors
have the potential to act as anti-tumoral agents, inhibiting cancer
cell signaling and reducing cell viability.15 In addition, NO may
exert an apoptotic effect by increasing ceramide levels through the
regulation of metabolic pathways involved in ceramide synthesis or
removal.16,17 Based on previous results on the rat C6 glioma cell
line, the aim of this study was to assess the effect of PAPANONOate
considering cell proliferation, ceramide trafficking and proteomic
signature of CCF-STTG1 and T98G glioma cell lines. Both cell lines
were derived from human gliomas with different oncogene muta-
tions.3 CCF-STTG1, as the C6 glioma cell line, has the PI3K/Akt
pathway constitutively activated, the former for mutation in PTEN
gene9,18 and the latter for the lack of PTEN expression,19 while the
T98G cell line is mutated in p53 (oncosuppressor).20
The diﬀerential proteomic analysis was based on two dimen-
sional diﬀerence in gel electrophoresis (2D-DIGE), MALDI mass
spectrometry, coupled with bioinformatics and immunoblotting, to
provide quantitative data characteristic of these two cell lines.
Results indicate that T98G compared to the CCF-STTG1 cell
line was more resistant to NO and was characterized by a
specific proteomic profile. The exposure of the CCF-STTG1 cell
line with a nitric oxide donor, PAPANONOate, resulted in a
partial inhibition of cell proliferation, which was associated
with a rapid and significant accumulation of ceramide at ER
levels. Indeed, T98G cells revealed an intracellular microenviron-
ment able to scavenge ROS and a mild UPR (unfolded protein
response) activation able to rescue tumor cells from NO exposure.
Validation of proteomic results by immunoblotting confirmed the
characteristic profile of the T98G cell line and the ability of these
cells to survive to NO donors probably by modulating specific
proteins. On the other hand, the proteomic profile, validated by
immunoblotting analysis, indicates a greater attitude to ER stress
response for CCF-STTG1 compared to T98G.
2. Results
2.1. Characterization of CCF-STTG1 and T98G cell lines: cell
proliferation and Akt signaling
CCF-STTG1, T98G, cell lines were characterized by diﬀerent
proliferating capacity as shown in Fig. 1. CCF-STTG1 showed a
duplication rate of 48 hours whereas T98G duplicate in 24 hours.
Based on T98G and CCF-STTG1 PTEN states, Akt activation was
assessed (Fig. 2). Akt, a downstream eﬀector of PI3K, is hyper-
activated when PTEN is mutated or lost.19 PTEN acts as a
negative control of the PI3K/Akt signaling pathway through its
phosphatase activity. The activation of Akt, expressed by the
pAkt/Akt ratio, plays an anti-apoptotic role by inducing the
overexpression of the antiapoptotic molecule B-cell-lymphoma
2 (Bcl-2).21 In CCF-STTG1 cells, Akt was hyperphosphorylated as
indicated by the higher pAkt/Akt ratio and Bcl2 was increased;
conversely, in T98G, the pAkt/Akt ratio was very low and Bcl2
expression was undetectable.
2.2. Eﬀects of nitric oxide on CCF-STTG1 and T98G cell line
proliferation
The eﬀect of NO exogenously delivered to CCF-STTG1 and
T98G, on cell proliferation, was assessed by cell treatment with
diﬀerent concentrations of NO-releasing molecules PAPANONOate,
SNAP or SPNO. In CCF-STTG, exposure to NO-releasing molecules
caused a 50% decrease of cell proliferation (Fig. 3A). On the other
hand, the same exposure did not alter cell proliferation of T98G
cells even when PAPANONOate concentration was drastically
increased (up to 1 mM) (Fig. 3B).
2.3. Eﬀects of nitric oxide on ceramide distribution in
CCF-STTG1 and T98G cell lines
The eﬀects of NO release on intracellular ceramide traﬃcking
were qualitatively assessed following the redistribution of
BODIPY-C5Cer, a fluorescent analogue of ceramide, able to
mimic the dynamic of the natural molecule. The distribution of
Fig. 1 CCF-STTG1 and T98G glioma cells proliferation. CCF-STTG1, T98G
cells were plated and grown in DMEM supplemented with 10% FCS for 24,
48, 72 and 96 hours. Then, at the indicated times the cells were washed,
detached and counted with trypan blue.
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ceramide in CCF-STTG1 and T98G cells after NO delivery was
determined by fluorescence. Cells were treated with BODIPY-
C5Cer (Fig. 4), and chased in the presence or absence of 0.4 mM
PAPANONOate. In CCF-STTG1 untreated cells, fluorescence
was accumulated in the perinuclear region, indicative of the
Golgi apparatus, (Fig. 4), whereas, as previously observed,13 in
NO-treated cells fluorescence was spread throughout the cell
with reduced accumulation in the Golgi region (Fig. 4). By
contrast, in T98G NO-treated cells, BODIPY-C5Cer distribution
was similar to control with a prevailing accumulation of
fluorescence in the Golgi region (Fig. 4).
2.4. Proteomic analysis
The CCF-STTG1 cell line showed a partial decrease of prolifera-
tion and ceramide accumulation in ER in response to nitric
oxide releasing agent PAPANONOate, whereas the T98G cell
line was resistant to NO administration.
The diﬀerent protein repertoire of CCF-STTG1 and T98G
glioma cells was investigated, at the molecular level, by 2D-
DIGE and protein identification was obtained by MALDI mass
spectrometry. The proteins diﬀerentially expressed are listed in
Table S1 (ESI†). From 2D-DIGE analysis, about 2500 spots per
gel were detected, 723 spots were included in the base set for
statistical analysis.
The characteristics of these two cell lines, in cell prolifera-
tion and ceramide distribution, were confirmed by proteomic
results which indicate that among identified spots, 56 were
diﬀerentially expressed between the two cell lines ( p-value o
0.01) and only 35 spots with a fold change over 1.5 were
considered and grouped according to their functional categories
(see Table S1, ESI†). For each spot, identification UniProtKB
accession (AC) numbers, protein name, gene name, theoretical
Mr(kDa)/pI, function and statistical analysis (fold change) are
indicated in Table S1 (ESI†). Fig. S1 (ESI†) shows a representative
map of CCF-STTG1 in panel A and T98G in panel B, the spots
diﬀerentially changed (p o 0.01 and fold change 41.5) are
indicated by numbers. The proteins, diﬀerentially expressed,
were grouped according to their functional category: chaperone
and stress response proteins, cytoskeletal proteins, intracellular
signal proteins, protein degradation, metabolic proteins and
other proteins. Mass spectrometry data of identified proteins
diﬀerentially expressed are listed in Table S2 (ESI†).
Fig. 2 Assessment of Akt signaling by immunoblotting of T98G and CCF-STTG1 cell line extracts: histograms represent the mean volumes, standard
deviations were calculated for the specific band of each experimental group. Data with asterisks indicate statistically significant diﬀerences between two cell
lines with a p valueo 0.05. Densitometric measurements were normalized against actin. Ratio of pAkt/Akt represents the amount of Akt activated protein.
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2.4.1. Chaperone and stress response proteins (Fig. 5).
Comparing T98G vs. CCF-STTG1 cell lines, the HSPs (heat
shock proteins) and cytoplasmic stress response proteins
HSPA4 (heat shock 70 kDa protein 4), HSP90AB1 (heat shock
protein HSP 90-beta), GSTP1 (glutathione S-transferase P),
PRDX1 (peroxiredoxin 1) were more abundant. Conversely,
HSP27 (heat shock protein beta-1) was less abundant and
mitochondrial HSPA9 (mortalin) was more abundant in T98G
compared to CCF-STTG1. In mitochondria, the interaction of
these proteins promotes the control of apoptosis by binding
survivin and p53.22 Conversely, proteins localized in endoplas-
mic reticulum, as PDIA3 (protein disulfide isomerase A3), P4HB
(protein disulfide isomerase), CALR (calreticulin), GRP78 (78 kDa
glucose-regulated protein) and TRA1 (heat shock protein gp96
precursor), were less abundant in T98G cells compared to CCF-
STTG1. CALR, PDI, GRP78 and TRA1 are involved in the
unfolding protein response (UPR).23,24
2.4.2. Cytoskeletal proteins and intracellular signal proteins
(Fig. 6). The majority of the cytoskeletal proteins, such as: F-actin
capping protein beta subunit (CAPZB), Vinculin (VLC), and two
isoforms of Vimentin, were less abundant in T98G compared to
the CCF-STTG1 cell line. Conversely, moesin (MSN) and the
Microtubule-associated protein RP/EB family member 1 (MAPRE1)
were more abundant in the T98G cell line.
Among proteins involved in intracellular signaling, Rho
GDP-dissociation inhibitor 1 (ARHGDIA) and Rab GDP dissociation
inhibitor beta (GDI2) were more abundant in CCF-STTG1 than
in T98G.
2.4.3. Protein degradation (Fig. 7). Comparing the two cell
lines, two subunits of the immunoproteasome activator protea-
some activator complex subunit 1 (PSME1), proteasome activator
complex subunit 2 (PSME2) and cathepsin D (CTSD), a lysosomal
aspartic protease, were less abundant in T98G. Importantly,
ubiquitin carboxy-terminal hydrolase L1 (UCHL1) was more
abundant in T98G compared to CCF-STTG1 with a fold change
of 14.86.
The global expression of metabolic proteins was similar in
the two cell lines, with only a few exceptions like the L-lactate
dehydrogenase B chain and transketolase that were more
abundant in the T98G cell line compared to CCF-STTG1.
Galectin 1 (LGALS1) was less abundant in T98G compared to
the CCF-STTG1 cell line. Other proteins diﬀerentially expressed
in T98G vs. CCF-STTG1 are listed in Table S1 (ESI†).
2.5. GRP78 expression level and localization (Fig. 8)
The ubiquitously expressed molecular chaperone GRP78 (glucose-
regulated protein) is generally localized to the ER (endoplasmic
reticulum) and it is specifically induced in cells under UPR.
Immunoblotting showed that levels of GRP78 in CCF-STTG1 are
twofold of those observed in T98G.Moreover, the GRP78 expression
level increased in CCF-STTG1 cells treated with PAPANONOate, but
was not modified in T98G cells treated with NO donors (Fig. 8A).
Images obtained using fluorescence microscopy demonstrated
that in CCF-STTG1 cells under normal growth conditions GRP78
was concentrated in the perinuclear region representative of the
ER/Golgi (Fig. 8B) in agreement with previous data.25 However,
treatments with PAPANONOate decreased its ER targeting,
resulting in GRP78 redirection possibly to a cytoplasmic vesicular
pattern and mitochondria (Fig. 8B). Conversely T98G cells PAPA-
NONOate did not show modification of their GRP78 level (Fig. 8A)
and localization (data not shown).
3. Discussion
CCF-STTG1 and T98G cell lines are multidrug-resistant26 and
NO donors were used to induce growth inhibition and chemo-
sensitization.10 In the present study exogenous NO, delivered
through PAPANONOate treatment, induced a decrease in cell
proliferation (o50%) and intracellular traﬃcking of ceramide
Fig. 3 Eﬀect of NO on CCF-STTG1 and T98G glioma cell proliferation.
CCF-STTG1 (panel A), T98G (panel B) cells were grown in DMEM supple-
mented with 10% FCS and incubated with diﬀerent concentrations of NO
donors for 4 hours. A chemiluminescence immunoassay for the quantifica-
tion of cell proliferation based on the measurement of BrdU incorporation
during DNA synthesis was used according to manufacturer’s instructions
(Roche). The incorporated BrdU was detected using a microplate reader. All
values are expressed as a mean  S.D. of at least three individual experi-
ments. Representative images of CCF-STTG1 and T98G morphology after
treatment with or without PAPANONOate. Images were analyzed on a
contrast phasemicroscope and digital images were acquired (magnification,
10; scale bar, 100 mm). CT: cells incubated without NO donors; NOC15:
cells incubated at 37 1C for 4 h with PAPANONOate; SNAP: cells incubated
at 37 1C for 4 h with S-nitroso-N-acetyl-DL-penicillamine; SPNO: cells
incubated at 37 1C for 4 h with Spermine NONOate.
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in CCF-STTG1 but not in the T98G cell line. Results provided
by both the Akt pathway and ceramide traﬃcking analyses
suggested a similar profile between human CCF-STTG1 and
rat C6 glioma cell lines;13,14 whereas the T98G cell line showed
a diﬀerent profile being Akt-harboring and p53 mutated. In
addition, Bcl2, a downstream eﬀector of Akt, playing a role in
the promotion of tumor malignancy, was not expressed in the
T98G cell line, suggesting that these cells may adopt alternative
mechanisms to growth and proliferate.
Proteomic analysis, by 2D-DIGE and mass spectrometry,
highlighted diﬀerences between the two cell lines, which could
contribute to explain their diﬀerent responses to NO exposure.
Three main protein functional classes were diﬀerently regulated in
T98G compared to CCF-STTG1: chaperones and stress response
proteins located in the cytosol and endoplasmic reticulum, cyto-
skeletal proteins and proteins involved in degradation.
T98G was characterized by higher expression levels of stress
response proteins, chaperones, redox cytosolic enzymes (i.e.
HSPA4, HSP90AB1, GSTP1 and PRDX1) and a mitochondrial
protein (HSPA9) and by lower expression levels of ER localized
proteins (i.e. PDIA3, P4HB, CALR, GRP78 and TRA1) and of
cytoskeleton associated proteins (i.e. HSP27).
Physiologically, molecular chaperones (like HSP90 and
HSP70) are known to control protein folding, turnover, diﬀer-
entiation and survival. In particular, it is known that their
expression is increased under cellular stress, promoting, in
tumors, malignant transformation and maintenance of cancer
homeostasis even in a hostile environment, as in the presence of
genetic lesions.27 In many tumors, the increment of molecular
chaperones provides a protection from stress-induced apoptotic
signals.28 In addition, increased GSTP1 and PRDXs have been
associated with an increment of cancer incidence and relapse.22
PRDXs are increased inmany tumors such as lung, breast cancer,
malignant mesothelioma and grade III and IV glioblastomas,27
promoting cell proliferation and enhancing resistance to H2O2-
induced apoptosis, radiation or chemotherapeutic treatments.29
Due to the diﬀerent role of chaperone and stress response proteins
in tumors compared to normal tissues their increment stimulated
tumor aggressiveness27,28 leading to hypothesize that the over-
expression of cytosolic stress response and redox protein generates
an intracellular environment, in the T98G cell line, able to counter-
act ROS damage and NO activity. Both cell lines expressed ER
chaperones involved in UPR response, in particular GRP78, CALR,
PDI3, P4HB and TRA1.
Furthermore, P4HB and PDIA3 were diﬀerently altered in
the two GBM cell lines, being increased in CCF-STTG1 and
decreased in T98G. By transplantation of diﬀerent human
glioblastoma biopsies in xenografts, animals developed two
diﬀerent tumor phenotypes: the high infiltrating low angio-
genic phenotype characterized by high expression of PDI and
the low infiltrating high angiogenic phenotype with low levels
of PDI, both phenotypes are representative of the diﬀerent
aspects of human brain tumor biology, in situ.30,31
To define the exact role of these molecules further analysis
will be required since the eﬀects of PDI in supporting tumor
survival and progression could be cell- and cancer-type dependent.
The UPR response, in fact, occurs when miss-folded proteins
accumulate in ER, generating ER stress, which leads to an increment
Fig. 4 Eﬀect of NO on intracellular distribution of BODIPY-C5Cer. CCF-STTG1 and T98G cells grown on a glass coverslip were incubated with 5 mM
BODIPY-C5Cer/BSA complex 1 : 1 (m/m) in DMEM for 30 min at 4 1C (START). After labeling, cells were incubated at 37 1C for 1 h without (CT) and with
400 mM PAPANONOate (NOC15). Representative fluorescence microscopy images are shown. All images were processed and printed using the same
conditions. Scale bar, 20 mm.
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of ER chaperone proteins, accompanied by a temporary block-
age of protein translation and by the activation of the ERAD
(endoplasmic reticulum associated degradation) complex.23 In
T98G, the levels of proteins controlling the UPR response were
lower compared to CCF-STTG1. Elevated protein synthesis, in
cancer cell, requires an increase of ER folding, thus an UPR
increase in cancer cell (i.e. up regulation of ER chaperones)
could provide an advantage for cell proliferation inducing
chemoresistance.24 Nevertheless, the prolonged and severe
activation of UPR leads to cell death by apoptosis. These results
could be supportive of a mild activation of UPR that could be an
adaptive response, as suggested by T98G cell line behavior.32
Indeed, in CCF-STTG1 cells, NO treatment increases ER stress,33
promoting ER functional impairment, which, in turn, compromises,
at least partially, the delivery of ceramide from ER to Golgi, with
a consequent ceramide accumulation in ER and growth arrest.
The dysregulation of proteins involved in cytoskeletal struc-
ture remodeling (i.e. vinculin, moesin and vimentin) and of
regulatory proteins (i.e. HSP27, MAPRE1 and ARHGDIA) can be
associated with the cytoskeletal reorganization, prominent in
T98G compared to the CCF-STTG1 cell line. Vimentin, a marker
of EMT (epithelial–mesenchymal transition or transformation)
overexpressed in cancer cells,34 was significantly less abundant
in T98G compared to CCF-STTG1 cell lines. Moreover moesin
Fig. 5 Histograms of diﬀerentially expressed metabolic proteins between
T98G and CCF-STTG1 belonging to the chaperones/stress response
proteins class. Fold change bars are in gray for cytosolic proteins, black
for mitochondrial proteins and light gray for protein localized in ER,
respectively. HSPA4 (heat shock 70 kDa protein 4), HSP90B (heat shock
protein HSP 90-beta), GSTP1 (glutathione S-transferase P), PRDX1 (perox-
iredoxin 1), HSP27 (heat shock protein beta-1), HSPA9 (mortalin), PDIA3
(protein disulfide-isomerase A3), P4HB (protein disulfide isomerase), CALR
(calreticulin), GRP78 (78 kDa glucose-regulated protein), TRA1 (heat shock
protein gp96 precursor).
Fig. 6 Histograms of diﬀerentially expressed metabolic proteins between
T98G and CCF-STTG1, belonging to cytoskeletal and intracellular signal
protein functional class. Fold changes bars are indicated in gray for
cytoskeletal proteins and black for intracellular signal proteins, respec-
tively. F-actin capping protein beta subunit (CAPZB), vinculin (VCL),
vimentin (VIM), moesin (MSN), microtubule-associated protein RP/EB
family member 1 (MAPRE1), Rab GDP dissociation inhibitor beta (GDI2)
and Rho GDP-dissociation inhibitor 1 (ARHGDIA).
Fig. 7 Histograms of diﬀerentially expressed metabolic proteins between
T98G and CCF-STTG1 belonging to protein degradation. Bars indicate the
fold change. Proteasome activator complex subunit 1 (PSME1), protea-
some activator complex subunit 2 (PSME2), cathepsin D (CTSD) and
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1).
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(MSN), involved in actin cytoskeleton control and cell migra-
tion, known to promote GBM proliferation and invasiveness,35
and the Microtubule-associated protein RP/EB family member
1 (MAPRE1), a master regulator of the microtubule,36 were
more abundant in the T98G cell line. It can be assumed that,
in T98G cells, this decrement may be due to a higher protein
catabolism instead of a decreased synthesis. This hypothesis is
supported by the low levels of heat shock proteins (HSP27 was
less abundant in T98G than CCF-STTG1) and by the cell turn-
over rate of T98G,26 which induces a persistent remodeling of
structural proteins.
The Rho family-Rho GDI system plays a crucial role in actin
cytoskeletal control and its down-regulation leads to Rho
GTPase activation signaling.37 The insensitivity to NO of T98G
cells may be due to a decrement of GDI2, a negative regulator of
the monomeric G protein Rab GTPases which inhibits the
exchange of GDP to GTP, stabilizing Rab proteins associated
with GDP. Rab proteins are involved in the vesicular traﬃcking
within cells, particularly Rab1 and Rab2 are implicated in
endoplasmic reticulum to Golgi apparatus transport.38 The
negative regulator GDI2 may contribute to blunt the sensitivity of
T98G to nitric oxide on ceramide distribution by aﬀecting the
ceramide vesicular transport between intracellular compartments.
Finally, also levels of PSME1, PSME2, cathepsin D, acting
as regulators of proteasomal degradation and promoters of
oxidative stress adaptation,39,40 and Galectin 1 have been found
altered.
Galectin 1 has been found dysregulated in many tumors
including astrocytoma, melanoma, prostate, colon and ovary
carcinomas and is often correlated with tumor aggressiveness
and metastatization.37 In T98G cells, the above proteins were
less abundant compared to CCF-STTG1, suggesting that due
to the partial eﬀect of NO in CCF-STTG1 (50% decrement of
cell proliferation), treatments able to modulate these proteins/
pathways should be associated with NO donors to improve
treatment response.
Furthermore, the diﬀerential expression between T98G and
CCF-STTG1 of ubiquitin carboxy-terminal hydrolase L1 (UCHL1),
more abundant in T98G (fold change +14.86), has to be considered.
The overexpression of UCHL1 leads to a down regulation of
E-cadherin and consequently anoikis resistance, independent
growth, anchoring and spreading. UCHL1 regulates key pro-
cesses in tumor progression and, particularly, the signaling of
b-catenin/TCF stabilizing the latter by de-ubiquitination. The
b-catenin/TCF mediates the expression of genes like c-myc, cyclin
D, c-jun, and survivin and others that are part of the oncogenic
pathway. Growing evidence suggests that UCHL1 is overexpressed
in many tumors and is associated with a poor prognosis.38 Recent
results demonstrate that the selective inhibition of UCHL1 by small
molecules and siRNA causes a decrease in tumor proliferation and
migration and increases the sensitivity of chemotherapeutic agents
inducing apoptosis.41
Overall these results suggest that nitric oxide treatment is a
potential anti-oncogenic agent that could overcome the resistance
to conventional therapeutic agents in some cancer cells. The NO
releasing donor, PAPANONOate, causes ceramide accumulation in
CCF-STTG1 cell lines. This accumulation can induce a switching of
the Akt hyperactivated signal,14,42 causing growth inhibition. From
proteomic data, the UPR stress response was more pronounced in
CCF-STTG1 than T98G, and this feature could interfere with ER
and Golgi traﬃcking, in particular under nitric oxide stress.
4. Materials and methods
Materials: Dulbecco’s modified Eagle’s medium (DMEM),
L-glutamine, sodium pyruvate solution, penicillin/streptomy-
cin, bovine serum albumin fraction V (BSA), fatty acid free-
BSA, phosphate buﬀer saline (PBS) were from Sigma-Aldrich
(St. Louis, MO, USA). Fetal calf serum (FCS) was from Euroclone
(Pero, Milano, Italy). (Z)-[N-(3-Ammoniopropyl)-N-(npropyl)amino]-
diazen-1-ium-1,2-diolate (PAPANONOate), S-nitroso-N-acetyl-DL-
penicillamine (SNAP) and (Z)-1-[N-[3-aminopropyl]-N-[4-(3-
aminopropylammonio)butyl]-amino]diazen-1-ium-1,2-diolate
Fig. 8 Immunoblotting of GRP78 on CCF-STTG1 and T98G cells before
and after PAPANONOate treatment. Histograms represent the mean
volumes and the standard deviations calculated for the specific band of
each experimental group. Data with asterisks indicate significant diﬀer-
ences between two cell lines with a p valueo 0.05 (panel A). The eﬀect of
NO on intracellular GRP78 localization. CCF-STTG1 and T98G cells grown
on a glass coverslip were incubated at 37 1C for 4 h with and without
400 mM PAPANONOate. Cells were stained with the anti-GRP78 antibody
followed by the FITC-conjugated secondary antibody. Representative
fluorescence microscopy images are shown. All images were processed
and printed under the same conditions. Scale bar, 20 mm (panel B).
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(SPNO) were from Alexis-Italia (Firenze, Italy). N-(4,4,-Difluoro-
5-,7-dimethyl-bora-3a,4a-diaza-s-indacene-3-pentanoyl) sphingosine
BODIPY-C5Cer was from Molecular Probes Europe (Leiden, The
Netherlands). Bromodeoxyuridine (BrdU) was from Roche Italia
(Milan, Italy). Primary mouse polyclonal goat anti-GRP78 and FITC-
conjugated rabbit anti-goat secondary antibody were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).
4.1. Cell cultures
Two human glioblastoma cell lines were used: the cell line CCF-
STTG1, p53 wild type and PTENmutated, and the T98G cell line
p53 mutated and PTEN wild type obtained from American Type
Culture Collection (Rockville, MD). The two cell lines were
grown at 37 1C in DMEM supplemented with 10% FCS, 1 mM
sodium pyruvate, 2 mM L-glutamine, 100 U ml1 penicillin,
100 mg ml1 streptomycin and 0.25 mg ml1 amphotericin B in a
fully humidified incubator containing 5% CO2 and 95% air. For
proteomic analysis 2D-DIGE, CCF-STTG1 and T98G cells were
plated (6  104 cells per cm2 and 1.5  104 cells per cm2
respectively) and maintained in DMEM plus 10% FCS for 72 h.
4.2. Proliferation assay
CCF-STTG1 and T98G cells were plated (6  104 cells per cm2,
1.5  104 cells per cm2 respectively) and maintained in DMEM
plus 10% FCS for 24 h. To assess proliferation the cells were
grown in DMEM plus 10% FCS for 24, 48, 72 and 96 hours then,
at the indicated times, the cells were washed twice with PBS,
detached by Trypsin/EDTA (0.025/0.001%) and counted with
trypan blue. To evaluate the eﬀect of NO the cells were then
incubated in DMEM plus 10% FCS for 4 h with or without the
following NO donors: 0.4–1 mM PAPANONOate, 0.4 mM SNAP,
0.4 mM SPNO. Based on C6 glioma cell results, a PAPANONOate
concentration of 0.4 mM was selected due to its maximal
inhibitory effect on cell proliferation.13 A chemiluminescence
immunoassay for the quantification of cell proliferation based
on the measurement of BrdU incorporation during DNA synth-
esis was used according to the manufacturer’s instruction
(Roche). The BrdU incorporated was detected using a microplate
reader (Wallac Victor2 from PerkinElmer).
4.3. Analysis of the intracellular distribution of fluorescent
ceramides
CCF-STTG1 and T98G cells plated at 4.5  104 cell per cm2 and
1.5  104 cell per cm2, respectively, were grown on a glass
coverslip. Then cells were incubated with 5 mM BODIPY-C5Cer
(as a 1 : 1 complex with fatty acid free BSA) in DMEM at 4 1C for
30 min and analyzed as previously described.13 Briefly, after
washing with DMEM plus 10% FCS and 0.34 mg ml1 fatty acid-
free BSA, cells were incubated 1 h at 37 1C in DMEM plus 10%
FCS with or without PAPANONOate. Cells were then washed
and fixed with 0.5% glutaraldehyde solution in PBS for 10 min
at 4 1C. The specimens were immediately observed and ana-
lyzed using a fluorescence microscope (Olympus BX-50)
equipped with a fast high resolution charge-coupled device
camera (Colorview 12) and dedicated software for image analy-
sis (analysis from Soft Imaging System GmbH).
4.4. Proteomic analysis
4.4.1. Two dimensional diﬀerence in gel electrophoresis
(2D-DIGE). Protein labeling, 2D separation and analysis were
performed as previously described.43 The pellet of each sample
was suspended in lysis buﬀer, assayed and labelled with the
CyDye fluorophores. A common internal standard for the two
cell lines was created. The internal standard was labeled with
Cy3, while samples were labeled with Cy5 and analyzed in
triplicate. The first dimension was performed on a IPGstrip3-
10 nonlinear (NL) immobilized pH gradient, 24 cm long, each
strip was loaded with 40 mg of internal standard and 40 mg of
the sample. Gel images were processed by 2D DeCyder software
for the quantitative analysis. Statistically significant diﬀerences
of 2D-DIGE data were computed by Student’s t-test ( p o 0.01).
To minimize false-positives, data were filtered by the following
criteria: false discovery rate (FDR) and 1.5 fold diﬀerence in
abundance (fold change). FDR correction was applied as a
multiple test for the correction method to keep the overall
error rate as low as possible.44 The fold change, provided by
DeCyder software analysis, indicates the value derived from the
normalized spot volume standardized against the intra-gel
standard.
4.4.2. Protein identification by MALDI-ToF mass spectro-
metry. Proteins were identified by peptide mass fingerprinting
(PMF) utilizing a matrix-assisted laser desorption/ionization
(MALDI) time-of-flight (TOF) mass spectrometer (Bruker Daltonics),
as previously described.43 In particular, search was carried out by
correlation of uninterpreted spectra with Mammalia entries in the
NCBInr 20070216 database (4626804 sequences; 1596079197
residues).
4.4.3. Bioinformatic data analysis of molecular pathways.
The MetaCore software (GeneGo, Inc., V6.3 build 25177), using
two diﬀerent bioinformatics analyses (‘‘Enrichment Ontolo-
gies’’ and ‘‘Analyze Network’’), was used for the interpretation
of diﬀerential protein expression from CCF-STTG1 and T98G
cell lines and for searching protein–protein interaction
networks.
4.5. Immunoblottings
Protein extracts (50 mg) from CCF-STTG1 and T98G cell lines
were loaded in triplicate and resolved on 12% polyacrylamide
gels, according to protein molecular weight. Membranes were
incubated with antibodies diluted as follows: polyclonal anti
Akt (cell signaling #9272) 1 : 1000, polyclonal anti Phospho-Akt
(Ser473 cell signaling #9271) 1 : 1000, anti BCl2 (cell signaling
#2876) 1 : 1000. For each gel MagicMarkt XP Western Protein
Standard (Life Technologies LC5602) was loaded. To confirm
2D-DIGE data, some selected diﬀerential expressed proteins
were validated by immunoblotting (Fig. S2, ESI†). After wash-
ing, membranes were incubated with anti-rabbit (GE Health-
care) or anti-goat (Santa Cruz Biotechnology) secondary
antibodies conjugated with horseradish peroxidase. Signals
were visualized by chemiluminescence using the ECL Plus
detection kit. Images were acquired using a LAS 4000 mini
(GE Healthcare) and were analysed using Image Quant TL
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(molecular dynamics). The data were normalized against actin
(Santa Cruz sc-7210 diluted 1 : 1000) and analyzed through a
Student’s t-test (p o 0.05).
4.6. Analysis of intracellular localization of GRP78 by
fluorescence microscopy
CCF-STTG1 and T98G cells plated at 6  104 cell per cm2 and
1.5  104 cell per cm2 respectively were grown on a glass
coverslip for 24 hours. Then the cells were treated with 0.4 mM
PAPANONOate for 4 h and fixed with 0.5% glutaraldehyde
solution in PBS for 10 min at 4 1C. The cells were then perme-
abilized with 0.2% Triton X-100 for 30 min at room temperature,
then blocked for 1 h with 0.2% Triton X-100, 5% BSA, 1% FCS in
PBS. After washing the cells were incubated 1 hour with the
primary antibody anti-GRP78 and stained with the secondary
FITC-conjugated antibody. Coverslips were mounted on glass
slides and the specimens were analyzed using a fluorescence
microscope (Olympus BX-50) equipped with a fast high resolution
CCD camera (Colorview 12) and image analytical software (Soft
Imaging System GmbH, Olympus, Munster, Germany).
5. Conclusions
Nitric oxide is emerging as a potential anti-oncogenic agent to
overcome chemo- and radio-resistance in cancer cells; although
its actions depend on the cell microenvironment. The treat-
ment with the NO donor, PAPANONOate, is able to partially
reduce the proliferation of CCF-STTG1, suggesting that NO
alone is not suﬃcient to inhibit the tumor cell growth. In
CCF-STTG1, an overexpression of proteins located in the endo-
plasmic reticulum and involved in the unfolded protein
response was observed, making this cell line sensible to NO.
By contrast, in the T98G cell line, a complex of cytosolic anti-
oxidant and stress response proteins provides resistance to
NO activity. This study, by providing diﬀerential ceramide
distribution and diﬀerential protein expression, following NO
exposure, identifies specific proteins as possible tumor aggres-
siveness markers of two human high grade glioma cell lines.
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